Poolbeg Pharma PLC (AIM: POLB, OTC: POLBF) Chief Executive Officer Jeremy Skillington and Principal Scientist Liam Tremble talked with Share Talk's Zak Mir about the company’s conference season.
We recently returned from a busy conference season and wanted to share the main messages, progress and next steps for POLB001 and our oral GLP-1 programme. Between ESMO in Berlin and BioEurope in Barcelona, we gained clinical insights, interest in partnering, and clarity on trial design as we prepare for a phase 2A CRS prevention trial and a proof-of-concept study for oral GLP-1.
Please see the questions for the interview:
- You recently attended the ESMO conference. Can you give us an overview of the conference – Liam
- Did you discuss POLB 001 at ESMO, and what was the general feedback? – Liam
- What were the key takeaways from the conference itself? – Liam
- Which leads me onto you, Jeremy, you just returned from BIO-Europe, how was the conference, and how do your current programmes, such as POLB 001 and your Oral GLP1 position itself, stand out at this partnering conference? - Jeremy
- BIO-Europe is all about connections. What types of partnerships are you seeking this year? You recently announced a collaboration with ACT to conduct your upcoming POLB 001 Phase 2a trial —so why attend the conference? Jeremy
- Is conference season over? Jeremy & Liam
Conference calendar and next events
The autumn run is not over. After BioEurope we planned continued follow ups at London Health Innovation Week and then the very significant ASH meeting in early December in Orlando. ASH is the major haemato‑oncology event where big pharma present emerging data and where clinical teams, investigators and partners congregate. We also have JP Morgan and other investor events on the horizon into the new year.
